Clinical trial
An Open Label, Pilot Phase II Study to Evaluate the Feasibility and Efficacy of CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT05854966 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Pilot Phase II Study to Evaluate the Feasibility and Efficacy of CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Lead sponsor
- Wake Forest University Health Sciences
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- December 31, 2024
- Completion date
- September 30, 2025
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia refractory, acute myeloid leukemia, in relapse, granulocytic sarcoma